A Canine Model of Human Alpha-L-iduronidase Deficiency
Overview
Affiliations
A disease discovered in three Plott Hound littermates was found to be associated with a profound and specific deficiency of alpha-L-iduronidase (mucopolysaccharide alpha-L-iduronohydrolase; EC 3.2.1.76) in fibroblasts and leukocytes. The pedigree was consistent with autosomal recessive inheritance. A markedly increased amount of dermatan sulfate and heparan sulfate was excreted in urine. Fibroblasts cultured from the skin of the affected dogs accumulated excessive 35S-labeled mucopolysaccharide; this accumulation could be decreased to a normal level by exogenous human high-uptake alpha-L-iduronidase (Hurler corrective factor) as well as by secretions of normal human or canine fibroblasts. The correction was inhibited by mannose 6-phosphate. Maturation of alpha-L-iduronidase in normal canine fibroblasts followed the pathway previously observed in human fibroblasts; no cross-reactive material was observed in the cells or in secretions from the fibroblasts of the affected dogs. The canine disorder thus resembles mucopolysaccharidosis I in all biochemical parameters tested; the clinical appearance of the animals is closest to Hurler-Scheie syndrome, a form of alpha-L-iduronidase deficiency of intermediate severity. The animal model should prove valuable for therapeutic experiments.
Lau Y, Iyer K, Shetye S, Friday C, Dodge G, Hast M J Orthop Res. 2024; 42(7):1409-1419.
PMID: 38368531 PMC: 11161329. DOI: 10.1002/jor.25813.
Zhang C, Gawri R, Lau Y, Spruce L, Fazelinia H, Jiang Z Mol Genet Metab. 2023; 138(2):107371.
PMID: 36709534 PMC: 9918716. DOI: 10.1016/j.ymgme.2023.107371.
Placci M, Giannotti M, Muro S Adv Drug Deliv Rev. 2023; 197:114683.
PMID: 36657645 PMC: 10629597. DOI: 10.1016/j.addr.2022.114683.
Effects of lithium administration on vertebral bone disease in mucopolysaccharidosis I dogs.
Lau Y, Peck S, Arginteanu T, Wu M, Lin M, Shore E Bone. 2021; 154:116237.
PMID: 34695616 PMC: 8671266. DOI: 10.1016/j.bone.2021.116237.
Differences in MPS I and MPS II Disease Manifestations.
Hampe C, Yund B, Orchard P, Lund T, Wesley J, McIvor R Int J Mol Sci. 2021; 22(15).
PMID: 34360653 PMC: 8345985. DOI: 10.3390/ijms22157888.